Schoolgirls with autism share experiences in young adult novel

A novel told from the point of view of a teenage girl with autism, written by schoolgirls with autism, has been published after the students – frustrated by their experience of a world that rejects and ignores them – decided to take matters into their own hands.

The pupils at Limpsfield Grange school, the country’s only state-funded residential school for girls with special needs, mined their own most painful – and uplifting – experiences to write M in the Middle, a young adult novel created with the help of their creative writing teacher, Vicky Martin.

“If society just realised the very simple fact that girls can have autism as well as boys, then the life of girls with autism would instantly be so much better because we wouldn’t be so scared of being labelled as weird, abnormal and strange,” said Francesca Warren, 14, one of the 70 girls at the school.

“Because people think autism is something only boys have – and because girls with autism behave completely differently to boys – girls have to constantly mask their condition,” Warren added. “But having to pretend to be someone else is debilitating and humiliating. And it doesn’t even work: people can get annoyed with you even when you mask [because they sense your inauthenticity].”

Warren sits with her friends in the office of Sarah Wild, the headteacher at Limpsfield Grange. Fizzing with as many different opinions as any other group of teenage girls, they only speak with one voice when it comes to the question of whether boys with autism have an easier life.

“Yes. Yes. Yes!” they shout in passionate union. “Ding. Ding!” whooped one girl, for added emphasis.

The hilarity quickly ebbed away. “I’m prey in a world of predators,” said 12-year-old Lauren Mittelmeier, quietly. “Life is really hard for girls with autism. Why is life so difficult?”

The struggle to get their condition recognised is just the start of the battle for girls with autism. Even when girls are diagnosed, their life doesn’t necessarily get any easier: there is virtually no specialist support, academic or otherwise, for girls.

Mittelmeier’s parents moved home from Dorset so their daughter could attend Limpsfield Grange school, in Oxted, Surrey. This is not unusual: another family moved from Cornwall. One other girl boards during the week and travels the 250 miles back to her home every weekend.

Mittelmeier said: “I was diagnosed at eight but my autism wasn’t acknowledged by my school. They just thought I was an idiot. They were trained to work with autistic people but I’m guessing it was boys they were trained for, not girls.”

There is no official data on autism diagnoses, although the National Autistic Society (NAS) is calling for local authorities to start collecting it, as well as ending the “autism diagnosis crisis” that sees children waiting for nine years and more for a diagnosis.

Statistics appear to show that more men and boys than women and girls have a diagnosis of autism. The study most quoted, written by Leo Kanner in 1943, found there were four times as many boys as girls. In later years, various studies, together with anecdotal evidence, put the men to women ratio at anything from 2:1 to 16:1.

But Sarah Wild, head of Limpsfield Grange, believes there are just as many girls with autism as there are boys.

She said: “I genuinely think there are equal numbers but the stereotype that it’s a male condition is self-perpetuating: the diagnostic checklists and tests have been developed for boys and men, while girls and women present completely differently.”

According to the NAS 2012 survey of 8,000 people with autism, just 8% of girls with Asperger syndrome were diagnosed before six years old, compared to 25% of boys. Only 21% of girls with Asperger’s were diagnosed by the age of 11, compared to 52% of boys. Many adult women who took part in the survey didn’t have a diagnosis at all: 10% compared to 5% of males.

An added problem facing girls and women with autism is that if their true condition isn’t identified, they are at risk of being misdiagnosed, said Wild. “If, for example, a clinician asks a girl with autism if she ‘hears voices’ or ‘sees people’, she’ll say ‘Yes’ because she’s being entirely literal – and then she’ll be misdiagnosed with schizophrenia or another mental health disorders,” she said.

The NAS survey suggests that 42% of females have been misdiagnosed, compared with 30% of males. Many women remain undiagnosed well into late adulthood until they self-diagnose: females in the NAS survey were more likely to have paid for their diagnosis (14% of females, compared with 9% of males).

Misdiagnosis and no diagnosis, as well as a lack of support, understanding and recognition once a correct diagnosis has been made, leave girls and women in a dangerous space. According to the NAS survey, 38% of females with Asperger’s have another serious mental health condition, including eating disorders and depression.

But momentum for change is starting to gather pace: in January, the National Association of Headteachers is holding a girls on the autism spectrum conference to prepare a call for action on the issue.

Before that, on 8 November, there is a private House of Lords roundtable organised by the autism and girls forum – itself set up just 18 months ago.

“We set up the forum because there is so much energy coming forward now from parents, academics, children and young people’s mental health services (Camhs), and teachers, that we’re missing identifying this group of girls,” said Professor Barry Carpenter, chair of the forum.

“The pattern we’re seeing is that these girls come badly unstuck in their teenage years. They manage to mask it when they’re younger, which means when they crumble, they don’t have any coping strategies and structures to fall back on for support,” he said.

The House of Lords roundtable has a quest, said Carpenter: “We need to engage political will, without which nothing will change. There needs to be a systematic review, either under the women and equalities committee or we need to set up a new, cross-governmental task force.

“We need to harness all this evidence coming to us and marshall it to incentivise more research, more help for schools and Camhs.

“We have a very vulnerable group of girls here,” he said. “I can’t personally live with the fact we’re not doing nearly enough to help them.”

M in the Middle is published by Jessica Kingsley Publications (£8.99). Click here to buy a copy for £7.37

Schoolgirls with autism share experiences in young adult novel

Novel Tips to Cope with Fall Allergy Season

As all also numerous of us know, environmental allergy symptoms can be debilitating and adjust the way we handle each day. Of program knowing what sets off our allergy symptoms is the initial phase to being ready to overcome them, but we can also attack allergens proactively so they reduce the influence on our lives. Each and every season has its very own obstacles, but with fall ragweed season in bloom, the following are some novel methods to cope, suggestions you might not have heard prior to.

Know Your Genuine Triggers

It sounds apparent, but if we don’t play shut consideration, we may be confusing what is actually triggering allergic reactions. This is specifically real when our sensitivities can adjust from 12 months to yr, or to various instances of the year. As an instance, we may possibly consider the trigger might be pollen outside, but it could just as very easily be dust or fur accumulating indoors, and vice versa. Is there something new in your office, this kind of as a new bouquet of flowers on their desk? Do your allergies flair up every time you go to the regional convenient retailer? If you are struggling and nothing at all you seem to be to do is helping, the 1st phase should be reassessing triggers, as you may be attempting to fix the incorrect dilemma. If your child has allergic reactions then understanding the prime allergies in kids is important to assisting deal with allergy symptoms.

Make sure your Atmosphere is Cost-free of Triggers

When you have identified triggers, now it’s time to decrease them. Simple sufficient, proper? Some ideas you may not have imagined of:

1. 
   Invest in an air purifier. Be sure to modify the air filters in your house and automobile A/C units, but if you’re nevertheless struggling even though indoors, an air purifier in your space can work wonders clearing the air of your allergic triggers.


2. 
   Steer clear of the Outdoors in the Morning: Is it pollen that’s ruining your day? Pollen counts are highest from 5a.m. to 10a.m., so get your everyday jog in the evening and otherwise stay away from getting outside if achievable.


3. 
   Really do not Hang Dry Laundry Outdoors: Due to the fact that is just hanging a giant pollen trap that you’ll be sporting or lying on every day, which is the single worst point you can do for allergies.

Try out Organic Treatments

There are a handful of all-natural techniques to help mitigate or alleviate your allergy symptoms that you may not know. Some are new, potent herbal formulation medicines that you would consider like a pharmaceutical to attack your signs and symptoms rapidly, but with no a lot of of the same side-results. Tried and correct every day supplements like stinging nettles, quercetin and bromlein can lessen the severity of your symptoms in excess of time as organic anti-histamines or anti-inflammatories. Other possibilities include taking a scorching shower and letting the steam ease your sinuses and lubricate occasionally dry sinuses. Greater yet, Neti Pots seem a lot more like genie lamps but can aid with stuffy noses but loosening up the mucus in your sinus cavity but also flushing out numerous of the allergens that are caught in your passageways. All that has to be completed is fill the pot with warm water and salt water and pour it into one particular nostril with your head tilted right up until it comes out the other natural. Try out this everyday, or when signs and symptoms are truly negative.

As you can see obtaining allergies is not a death sentence of sorts. It can make one’s lifestyle far more difficult but currently being mindful of your surroundings and taking precaution can assist people who endure from allergic reactions venture out into the planet. Know what will make your allergies start off acting up and avert this from taking place by becoming ready. Allergy symptoms do not have to rule your lifestyle as there are many a lot more choices to aid the signs and symptoms than there was in the past. Get prepared to make this the very best allergy season of your existence.

Novel Tips to Cope with Fall Allergy Season

FDA Areas Clinical Hold On Phase 3 Trial Of Novel Anticoagulant

A extremely promising novel anticoagulant method now appears to be in serious issues. Regado Biosciences announced these days that the FDA had positioned a “clinical hold” on patient enrollment and dosing in the REGULATE-PCI trial, which is testing the Revolixys anticoagulation technique. Revolixys consists of the Factor IX inhibitor pegnivacogin and an agent, anivamersen, which reverses its anticoagulant result.

REGULATE-PCI is a phase 3 trial evaluating Revolixys to bivalirudin (Angiomax, The Medicines Firm) in 13,000 patients undergoing PCI. The principal investigators of the trial are A. Michael Lincoff (Cleveland Clinic), Roxana Mehran (Mount Sinai), and John Alexander (Duke Clinical Investigation Institute).

The FDA action is not fully unexpected. On July 2 the company announced that patient enrollment in the trial had been paused when the Data Safety Monitoring Board (DSMB) initiated an unplanned assessment of trial data. The company explained the DSMB would “conduct a full evaluation of security and treatment advantage-danger ratio of all individuals enrolled to date (3234) with a emphasis on significant adverse occasions connected to allergic reactions.”

Regado mentioned the clinical hold was taken by the FDA “to formalize the involvement of the FDA in any selection to re-initiate enrollment and dosing in the trial in the future.” The organization CEO stated that “any recommendation to re-initiate patient enrollment in REGULATE-PCI will be based mostly on the DSMB’s conclusions and would constantly be implemented in agreement with FDA.” The two the firm and the trial’s principal investigators stay blinded to the examine benefits.

FDA Areas Clinical Hold On Phase 3 Trial Of Novel Anticoagulant

FDA Approves Novel Implanted Sensor To Monitor Heart Failure

The FDA announced these days that it had authorized the CardioMEMS Champion HF Technique. The small implantable device offers daily pulmonary artery strain measurements to guidebook doctors in their therapy of  NYHA Class III heart failure individuals who have been hospitalized for heart failure in the preceding 12 months. The program consists of 3 elements: a tiny everlasting sensor implanted in the pulmonary artery, a catheter-based mostly delivery technique, and a method that acquires and processes PA pressure measurements from the implanted keep track of and transfers the information to a secure database.

CardioMems had a rocky street to approval. Two separate instances, in 2011 and in 2013, the FDA’s Circulatory Program Units Panel agreed that the device was safe but that it had not been proven to be powerful or that the positive aspects of the device outweighed the hazards. Most of the discussion revolved all around the pivotal CHAMPION trial which enrolled 550 heart failure sufferers. The FDA explained today that it “believes that there is sensible assurance that the device is safe and successful for heart failure management with the goal of reducing the rate of heart failure-associated hospitalizations in specific sufferers.”

The FDA stated that it would need CardioMems to conduct “a thorough Publish-Approval Examine to continue to learn about the device’s efficiency when used outdoors the context of a clinical research.”

CardioMEMS was founded by cardiologist Jay Yadav, who is also the company’s CEO. The firm is partly owned by St. Jude Healthcare, which has mentioned that it ideas to entirely acquire the company in the first half of 2014.

“Heart failure is one of the most typical causes for hospitalizations for folks aged 65 and older,” mentioned Christy Foreman, director of the Office of Gadget Evaluation in the FDA’s Center for Units and Radiological Health, in an FDA press release. “The goal of this very first-of-its-sort implantable wireless gadget with remote monitoring of pulmonary artery pressure is to lessen heart failure-connected hospitalizations.”

There is widespread agreement that heart failure signify an massive and increasing burden on the well being care program. CardioMems cites American Heart Association estimates that direct and indirect expenses of heart failure in 2012 equalled $ 31 billion. However, it is unclear no matter whether the gadget will be capable to fulfill the high expectations suggested in this statement from a CardioMems representative:

Not only is this FDA approval going to influence the quality of lifestyle for patients, it will also conserve up to 40% in Medicare expenditures related to heart failure, which is the largest part of the Medicare price range.

FDA Approves Novel Implanted Sensor To Monitor Heart Failure

FDA Rejects Novel Novartis Drug For Acute Heart Failure

Novartis Novartis said today that the FDA had issued a full response letter for the biologics license application for RLX030. The drug, also identified as serelaxin, is a recombinant form of the naturally taking place human hormone relaxin-two, which has been identified to assist ladies modify to the cardiovascular changes that arise during pregnancy.

The FDA selection was not unexpected considering that earlier this 12 months its Cardiovascular and Renal Medicines Advisory Committee voted unanimously towards approval. The rejection occurred despite the reality that the drug received a ”breakthrough therapy” designation from the FDA final yr. Serelaxin was also turned down for approval in Europe earlier this yr.

Novartis mentioned it plans to carry on advancement of the drug. ”We continue to feel RLX030 has the potential to be an essential treatment method for AHF and have been encouraged by feedback from FDA advisory committee members noting the information are intriguing,” explained a business executive. “In accordance with the FDA’s tips we will carry on to expedite our clinical trial system to construct the supporting physique of proof.”

The BLA relied heavily on data from the the pivotal phase III Loosen up-AHF research. Novartis stated it was “continuing to expand the data supporting the efficacy of RLX030 in acute heart failure with an comprehensive global clinical plan, like the Relax-AHF-two trial which will enroll more than 6,300 sufferers.”

FDA Rejects Novel Novartis Drug For Acute Heart Failure

FDA Approves Novel Merck Drug To Stop Heart Attacks And Strokes

The FDA nowadays approved vorapaxar (Zontivity), Merck’s Merck’s after-troubled platelet receptor antagonist, to minimize the danger of myocardial infarction (heart assault), stroke, cardiovascular death, and revascularization procedures. The drug is accepted for use in people with a background of MI or peripheral arterial illness. The approval represents an wonderful turnaround for a drug that had knowledgeable nearly as several ups and downs as an amusement park roller coaster.

Vorapaxar is the 1st in a new drug class recognized as protease-activated receptor-1 (PAR-one) antagonists. By stopping the capability of platelets to stick collectively and kind blood clots, the drug can support prevent MI and stroke. But it also increases the chance of bleeding, which includes daily life-threatening and fatal bleeding. Simply because the threat of significant intracranial bleeding is specially large in individuals who have had a stroke, a transient ischemic assault, or bleeding in the head, use of the drug is contraindicated in these groups. The drug’s label consists of a boxed warning about the chance of bleeding. The FDA stated the drug will be dispensed with a patient Medication Guidebook.

Vorapaxar appeared to be all but dead a number of years in the past following unacceptably substantial significant bleeding costs had been identified in two huge clinical trials. But hopes for the drug resurfaced with a new examination of one of these trials, the TRA2P trial. In a statement to the press, Ellis Unger, director of the FDA’s Workplace of Drug Evaluation I, mentioned that the trial showed that “in sufferers who have had a heart assault or who have peripheral arterial illness, this drug will lower the risk of heart assault, stroke, and cardiovascular death…  Zontivity lowered this danger from 9.five percent to seven.9 % over a three-yr period – about .5 percent per yr.”

In January the FDA’s Cardiovascular and Renal Medication Advisory Committee voted 10-one in favor of approval for vorapaxar.

FDA Approves Novel Merck Drug To Stop Heart Attacks And Strokes

Can a New Novel Conserve the Whales Against Navy’s Sonar Testing

Sonar Testing and Harm to Whales and Dolphins

There’s an previous adage that the surroundings is never saved — just continually being saved. And the U.S. Navy’s testing and training with higher-intensity lively sonar is a ideal illustration.

When it comes to the next 5 many years of instruction and testing routines in Southern California and Hawaii, the Navy’s not just up to its previous tricks, it’s moving forward with actions that, by its very own estimate, will inflict an 11 fold increase over the harm the Navy estimated for its last 5 many years of training. The National Marine Fisheries Support — the company charged with defending whales and dolphins — has authorized practically 9.6 million situations of temporary hearing loss and considerable disruptions of crucial conduct, thousands of long term injuries, and more than a hundred deaths. (Huffington Submit, one/27/14)

Can a Novel make an effect?

Go through a book that depicts the impact on our planet that this kind of testing has on marine daily life and daily life on the planet prior to it gets a major motion image (film rights have presently been sold).  I just finished reading through this brilliant novel, The Emissary, by Patricia Cori. The story is propelled from page 1 by many seemingly unrelated occurrences. Inside minutes of each and every other, 3 events take spot about the globe. In Los Angeles, hundreds of blackbirds drop out of the sky, zapped to their death, mid-flight. Concurrently, on the East Coast, in Maine, residents awaken to discover miles of beach covered in tens of 1000′s of dead fish. And in New Zealand, 150 whales and dolphins lay dead or dying, like gigantic boulders thrown from the ocean, on a resort seashore. Overhead, a unusual grid-like pattern in the clouds hangs reduced and menacing, in excess of the desperate scene.

The Emissary packs a scrumptious journey filled with intrigue and strategies and whisks you off on a trip that you don’t want to get off. Via the story that unfolds it also invites all of us to search at the part we perform in our evolving world. By way of the fast-paced occasions that occur, deftly led by our heroine Jamie Hastings, readers are guided to turn into emissaries as well—sent on a really particular mission that is born from author Patricia Cori’s passion in the world. That mission for some may possibly be to curl up in a chair, to give themselves a respite from life’s demands, and get lost in the voyage of The Emissary. For other people, the unique mission turns into a journey of self-exploration, of appreciation of all creatures fantastic and little, and an invitation to completely embrace our roles as ambassadors of our planet. It is a story of hope, commitment, and perseverance. But far more, it is a story of love amongst a very specific female and those who generate the songs in our waters. May we use the messages contained within The Emissary to help us ensure people songs proceed forever.” —Christine Andrew, Enlightening Radio

The Emissary, a Novel by Patricia Cori Just launched on March 2014.

 About the Writer

She’s been known as a “real existence Indiana Jones” and a living model of the adventurous spirit and seeker within us all. Internationally acclaimed writer Patricia Cori is one particular of the most effectively-recognized and established authorities on the realms of the mystic. In 2012, she founded the international nonprofit association Save Earth’s Oceans, Inc., committed to restoring the stability of our fragile ocean ecosystems and conserving the whales and dolphins from whaling, slaughter, and exploitation.

We have naturally reached a point where we cannot basically turn a blind eye to what is happening to our oceans.  If only the dolphins and whales could communicate to us about what we have accomplished to them in their habitat.   I felt like this guide does a great occupation of currently being that voice and helping each and every of us to wake up and recognize it is our duty to become conscious and involved in this battle.

Healthier Blessings,

Sandy

Get your copy of newly released The Emissary right here.  Pass it on and let’s help increase awareness and hopefully obtain far more traction for this battle.

Visit our Healthier Residing Website

Can a New Novel Conserve the Whales Against Navy’s Sonar Testing

Early Accomplishment For Novel Novartis Heart Failure Drug

A huge clinical trial testing a novel compound from Novartis Novartis for continual heart failure has been stopped early for efficacy. In a press release Novartis mentioned the Data Monitoring Committee had advisable early closure of the PARADIGM-HF trial because the trial had demonstrated a important reduction in the mixed main endpoint of cardiovascular death and heart failure hospitalization.

PARADIGM-HF randomized sufferers with heart failure and lowered left ventricular ejection fraction to both the ACE ACE inhibitor enalapril or LCZ696, an Angiotensin Receptor Neprilysin Inhibitor (ARNI) that is the first in its class. Almost 8,500 sufferers were studied in the trial, which Novartis mentioned produced it the greatest-ever trial in heart failure.

“The outcomes of PARADIGM-HF are genuinely impressive” said heart failure specialist Milton Packer, a Principal Investigator of the trial. “The finding that treatment with LCZ696 was superior to currently recommended doses of enalapril has profound implications for the care of patients with chronic heart failure. We now have compelling proof that supports LCZ696 as a new cornerstone in the management of persistent heart failure.”

Novartis mentioned the trial findings will be presented at a health care conference in the potential and that the company will seek to obtain approval for the drug with regulators.

The announcement follows by only a couple of days the rejection of a diverse Novartis heart failure compound, serelaxin, by an FDA advisory panel.

Early Accomplishment For Novel Novartis Heart Failure Drug

Costa guide award won by Nathan Filer for debut novel, The Shock of the Fall

Nathan Filer with his Costa award-winning guide. Photograph: Tal Cohen/EPA

Judges for 1 of the UK’s most prestigious literary prizes on Tuesday heralded a major new talent when they named psychological health nurse Nathan Filer winner of the 2013 Costa guide award for a moving account of schizophrenia and grief.

Filer won towards far more fancied contenders, not least Kate Atkinson, for his debut novel The Shock of the Fall.

The novelist Rose Tremain, who chaired the judges, stated: “For a 1st novel it is astonishingly positive-footed … I believe there is real pleasure about this winner.”

The book is narrated by Bristol boy Matthew from the age of five to his early 20s and is a gripping account of his descent into schizophrenic sickness following the death of his younger brother. It is informed when he is at school, when he is smoking also much marijuana in a grotty flat and from the psychiatric wards he ends up in.

Tremain stated, however, it was not just about schizophrenia: “It is about grief and this is a topic we all have expertise of. It is grief analysed but handled completely with no sentimentality. It gets near that and there had been moments when I received concerned, but it always avoids them.”

The Costa prize is unusual in that it pits five category winners – novel, first novel, biography, children’s and poetry – against each and every other for the best £30,000 prize like evaluating chicken curry with custard, as one former judge mentioned.

Atkinson had been powerful favourite to win for her eighth novel Lifestyle Following Lifestyle, which would have been her 2nd Costa win. It was not to be. “There’s often going to be a bookies’ favourite,” stated Tremain. “By bookies who haven’t go through the books.”

Filer, aged 33, has worked in psychiatric wards for far more than a decade. When last asked about it he said he meant to carry on with the odd shift and to hold his nursing registration up.

Tremain said: “To take this kind of a marvellously articulated factor from his professional lifestyle and bring it to lifestyle in the way he has is such an extraordinary achievement.”

The guide is the merchandise of Filer’s MA in innovative creating at Bath Spa University, in which he now lectures.

Last year it was the topic of a fierce 11-way bidding war by publishers – constantly hunting for the following possible Mark Haddon and his The Curious Incident of the Puppy in the Night-Time. It was at some point secured by HarperCollins, who presented a six-figure deal.

Filer was plainly not expecting to win, nor was his new wife Emily who he married on Saturday. “I was 100% certain he was not going to win,” she mentioned.

He was thrilled even though. “I wrote this guide simply because I want to share it, I was not creating it for myself… I often desired men and women to read through it and winning this means far more and much more folks will read through it so I am absolutely delighted by that.”

Filer mentioned he had felt a accountability not to propagate myths close to psychological well being and would carry on nursing shifts, like one coming up on Sunday.

There is now an expectation, he is the new creating talent on the block. “Of course a pressure comes with something like this as effectively as the reward but I am not going to sit here and bemoan a pretty issue that has just happened.”

Tremain said the five contenders made up a quite excellent checklist and all the books were talked about in the two-hour meeting. “In the end it was not quite tough for us to agree.” Though “not fairly unanimous” there was no blood, Tremain mentioned. “It was a extremely excellent natured and articulate jury. It was a very entertaining afternoon.”

Filer’s Costa win will be daily life-altering, Tremain acknowledged. “There’s usually a risk with a first-time winner – is this a one particular guide wonder? You will not know. But this extraordinary fashion and self-assurance is not an simple thing to do. If I had to bet on it I would say there are far more books in this writer.”

He is the fifth first novelist to win, with prior winners like Atkinson who won in 1995 for Behind The Scenes at the Museum. The final 1 was Stef Penney in 2006 with The Tenderness of Wolves.

The other books missing out on Tuesday were Lucy Hughes-Hallett’s biography of Gabriele D’Annunzio, The Pike Michael Symmons Roberts’ poetry assortment Drysalter, and Chris Riddell’s children’s book Goth Lady and the Ghost of a Mouse.

The prize, now in its 42nd year, unashamedly rewards enjoyability. It was recognized as the Whitbread prize from 1971 to 2005.

This year’s nine-robust judging panel incorporated actor Natascha McElhone, Pointless expert Richard Osman, singer Sharleen Spiteri, and authors and writers Gerard Woodward, Emma Kennedy, Anne de Courcy, Matthew Cain and John Burnside.

Costa guide award won by Nathan Filer for debut novel, The Shock of the Fall